enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
3.390
+0.040 (1.19%)
Nov 4, 2024, 4:00 PM EST - Market closed
enVVeno Medical Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
31
Market Cap
59.45M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
111, Inc. | 2.03B |
Enzo Biochem | 31.91M |
Cryo-Cell International | 31.84M |
Aligos Therapeutics | 7.97M |
Omega Therapeutics | 6.31M |
Shattuck Labs | 4.12M |
Serina Therapeutics | 3.17M |
Syros Pharmaceuticals | 386.00K |
NVNO News
- 3 years ago - Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann - Accesswire
- 3 years ago - Hancock Jaffe To Rebrand As enVVeno Medical - Benzinga
- 3 years ago - Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs - Accesswire
- 3 years ago - Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021 - Accesswire
- 3 years ago - Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics - Seeking Alpha
- 3 years ago - Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules - Accesswire
- 3 years ago - Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve - Benzinga
- 3 years ago - Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting - Accesswire